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Abstract
Background: The disintegrin metalloproteinase 10 (ADAM10) is the main α-secretase acting in the non-amyloidogenic
processing of the amyloid precursor protein. This study assesses whether ADAM10 is present in cerebrospinal fluid
(CSF), and whether it has potential as a biomarker for Alzheimer’s disease (AD).
Methods: ADAM10 was characterized in human CSF samples by immunoprecipitation and western blotting using
antibodies specific for different domains of the protein and by ultracentrifugation in sucrose density gradients. Samples
from AD patients (n = 20) and age-matched non-AD controls (n = 20) were characterized for classical CSF biomarkers,
Aβ42, T-tau, or P-tau by ELISA, and assayed for soluble ADAM10 levels by western blotting.
Results: We found that ADAM10 is present in human CSF as several distinct species: an immature form retaining the
prodomain (proADAM10; ~ 80 kDa), a mature unprocessed full-length form (ADAM10f; ~ 55 kDa), and a truncated large
soluble form released from the membrane (sADAM10; ~ 50 kDa). Fractionation by ultracentrifugation on sucrose density
gradients showed that the ADAM10f and sADAM10 species form large complexes. Immunoblotting revealed a significant
decrease in ADAM10f and sADAM10 in AD CSF compared to control CSF, while proADAM10 levels remained unaltered.
Conclusions: Several forms of ADAM10 are present in CSF, mainly assembled as high-molecular weight complexes. The
determination of the levels of mature forms of CSF-ADAM10 may be useful as a biomarker for AD.
Background
The amyloid-β peptide (Aβ) is a key pathological effector
of Alzheimer’s disease (AD) [1]. Aβ is a short polypeptide
generated by processing of a larger type I transmembrane
spanning glycoprotein, the amyloid precursor protein
(APP), through the successive action of proteolytic en-
zymes called β-secretase and γ-secretase [2, 3]. APP can
undergo alternative proteolytic processing [4]; indeed in
the main pathway APP is cleavage by α-secretase within
the Aβ domain, precluding Aβ formation [5]. Several
members of membrane-bound disintegrin metalloprotein-
ase (ADAM) family have been proposed as α-secretases,
mainly ADAM10, ADAM17 (TACE), and ADAM9 [6],
but other ADAM family members, such as ADAM8, may
also cleave APP [7]. However, convincing evidence,
particularly data from in vivo studies [8, 9], indicates that
ADAM10 is the enzyme acting as the main physiologically
relevant α-secretase [10].
The major neuronal β-secretase, the beta-site APP
cleaving enzyme 1 (BACE1; [11] is present in CSF [12]
in a soluble and truncated form, and increased
β-secretase activity and BACE1 protein levels have been
investigated as biomarkers for AD [13–16]. The pres-
ence in CSF of γ-secretase components, and particularly
components of the catalytic subunit presenilin-1, have
also been assessed recently as AD biomarkers [17, 18].
However, to our knowledge, only ADAM17/TACE activ-
ity has been assessed in both CSF [19] and plasma [20,
21]; while the potential of ADAM10 as an alternative
AD biomarker has so far only been investigated in plate-
lets [22, 23] and other blood cells [24]. ADAM prote-
ases, similar to BACE1, are type I transmembrane
proteins, but also include secreted isoforms [6]. Indeed,
ADAM10 and ADAM17 have been shown to be secreted
outside cells in exosomes [25]. Recently, an in-depth
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analysis of the human CSF endopeptidome enabled iden-
tification of several ADAM10 peptides [26].
In this study, we investigated the occurrence of
ADAM10 in human CSF and whether altered levels of
this protein occur in AD. We have characterized the
full-length and truncated forms of ADAM10 in CSF, as
well as immature forms of the protein that need to be
taken into consideration for the design of an appropriate
strategy for development of further assay approaches.
We report that the full-length and truncated forms of
ADAM10, but not the immature forms, decrease in AD
CSF compared to control CSF.
Methods
Patients
CSF samples were obtained from the Clinical Neuro-
chemistry Laboratory (Mölndal, Sweden) from patients
who sought medical advice because of cognitive impair-
ment. In total, 27 patients with AD (7 men and 20
women, mean age 71 ± 1 years) and 26 age-matched
non-AD controls (NADC; 18 men and 8 women, mean
age 70 ± 2 years) were included. Patients were designated
as AD or NADC according to CSF biomarker levels
using cutoffs that are > 90% specific for AD: total tau
(T-tau) > 400 ng/L, P-tau > 60 ng/L and Aβ42 < 550 ng/L
[27]. For details about classical CSF biomarker levels see
Table 1. All AD patients fulfilled the 2011 NIA-AA criteria
for dementia [28]. No other clinical data were available for
the subjects. The CSF samples used for the present study
were de-identified leftover aliquots from clinical routine
analyses, following a procedure approved by the Ethics
Committee at University of Gothenburg. This study was
also approved by the Ethics Committee at the Miguel
Hernandez University.
Cell cultures
For obtaining conditioned cell-culture medium CHO
cells (450,000 cells/well) were grown in six-well plates
for 48 h in Dulbecco’s modified Eagle’s medium
(DMEM) plus GlutaMAX™ (Gibco® Life Technologies,
Paisley, UK) supplemented with 5, 1 or 0.5% fetal bovine
serum (FBS; Gibco) and 100 μg/mL penicillin/strepto-
mycin (Gibco). After 48 h, the cell medium was recol-
lected, centrifuged for 15 min at 1500×g at 4 °C, and
frozen for future analysis.
Western blotting and biochemical measurements
Samples of CSF (30 μL) and cell medium (20 μL) were
denatured at 98 °C for 5 min and resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) under reducing conditions. Following elec-
trophoresis, proteins were blotted onto nitrocellulose
membranes (Bio-Rad Laboratories GmbH, Munich,
Germany). Bands of ADAM10 immunoreactivity were
detected using an antibody specific for the mid-region of
ADAM10 (hereafter referred to as the ectodomain anti-
body; rabbit polyclonal; OAGA02442, Aviva Systems
Biology, San Diego, USA), an anti-N-terminal (rabbit
polyclonal, ab39153, Abcam, Cambridge, UK), and
anti-C-terminal ADAM10 antibody (rabbit monoclonal;
ab124695, Abcam). Blots were then probed with the ap-
propriate conjugated secondary antibodies, and imaged
on an Odyssey Clx Infrared Imaging System (LI-COR
Biosciences, Lincoln, NE, USA). Band intensities were
analyzed using LI-COR software (Image Studio Lite). All
samples were analyzed at least in duplicate. Ponceau
staining served to monitor potential loading inaccuracies
in individual blots. Immunoreactive ADAM10 signal for
each band was normalized to the immunoreactivity of
the corresponding band from a control CSF sample
(aliquots from the same sample), resolved in all the blots.
For the estimation of the (50 + 55 kDa)/80 kDa ratio for
each sample (see the “Results” section), the unprocessed
immunoreactivity for each band was considered.
Serum and CSF albumin concentrations were mea-
sured by immunonephelometry on a Beckman Image
Immunochemistry system (Beckman Instruments, Beck-
man Coulter). The CSF/serum albumin ratio was calcu-
lated as CSF albumin (mg/L)/serum albumin (g/L). CSF
albumin levels were also estimated by western blotting
using a rabbit polyclonal antibody (SAB2100098,
Sigma-Aldrich, Saint Louis, USA).
Sucrose density gradient ultracentrifugation
ADAM10 complexes were fractioned by ultracentrifuga-
tion at 250,000×g on a continuous sucrose density gradi-
ent (5–20%) for 4 h at 4 °C in a Beckman TLS 55 rotor.
CSF aliquots (65 μL) were carefully loaded onto the top
of the gradient containing 2 mL of 0.15 M NaCl, 50 mM
MgCl2, and 0.5% Brij 97 in 50 mM Tris-HCl (pH 7.4).
After centrifugation, ~ 14 fractions were collected gently
from the top of the tubes. Enzyme markers of known
sedimentation coefficient, β-galactosidase, catalase, and
Table 1 Demographic data and classic CSF biomarker levels
Group Age (years) n (gender) CSF Aβ42 (pg/mL) CSF T-tau (pg/mL) CSF P-tau (pg/mL)
NADC 70 ± 2 [55–88] n = 26 (8F/18M) 773 ± 29 [1010–561] 238 ± 13 [138–365] 36 ± 2 [21–51]
AD 71 ± 1 [55–86] n = 27 (20F/7M) 414 ± 15* [544–251] 689 ± 48* [1420–443] 88 ± 5* [164–61]
Patients were designated as NADC or AD according to CSF biomarker levels using cutoffs as described in the “Methods” section (and ref. [27]). The data represent
the means ± SEM. The ranges of values for each variable are also indicated. F female; M male. *Significantly different (p < 0.001) from the NADC group
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alkaline phosphatase were used in the gradients to deter-
mine the approximate sedimentation coefficients.
Measurement of T-tau, P-tau, and Aβ42 by ELISA
Total tau (T-tau), phosphorylated tau (P-tau), and Aβ1–42
(Aβ42) concentrations in CSF were measured using
INNOTEST ELISA methods (Fujirebio Europe, Gent,
Belgium).
Statistical analysis
All the data were analyzed using SigmaStat (Version 3.5;
Systac Software Inc.) using a Student’s t test (two-tailed)
or a Mann-Whitney U test for single pairwise compari-
sons, and determining the exact p values. The results are
presented as means ± SEM, and the correlation between
variables was assessed by linear regression analyses.
Results
ADAM10 is present in human CSF as several species
ADAM10 is expressed as a 748 amino-acid-residue type
I glycoprotein composed of an N-terminal signal se-
quence followed by a prodomain, a metalloprotease do-
main, a disintegrin domain, a cysteine-rich region, a
transmembrane helix, and a cytoplasmic region (Fig. 1a).
In a previous in-depth LC-MS analysis of human CSF
peptides, we were able to identify 38 small peptides
matching parts of the ADAM10 sequence, including the
prodomain and the cysteine-rich region close to the
transmembrane domain [26] (see also Fig. 1a and
Additional file 1: TableS1). Analysis of control CSF sam-
ples by SDS-PAGE and western blotting using ectodo-
main and N-terminal ADAM10 antibodies revealed
three immunoreactive species with apparent molecular
masses of ~ 80, 55, and 50 kDa (Fig. 1b), and a broad
band of ~ 70 kDa (expected molecular mass of albumin).
Immunoblotting with an anti-C-terminal ADAM10 anti-
body detected the 80 and 55 kDa, as well a broad
70 kDa band, but not a 50 kDa band (Fig. 1b), suggesting
that the 50 kDa form of CSF ADAM10 is C-terminally
truncated. To further examine the identity of ADAM10
immunoreactive species in human CSF, we performed
immunoprecipitation/western blot analysis (Fig. 1b). CSF
samples were immunoprecipitated using the anti-N-ter-
minal ADAM10 antibody, and blots stained with the
ectodomain antibody detecting the 80 kDa species and a
strongly immunoreactive 50–55 kDa band. These bands
were not observed in negative immunoprecipitation con-
trols, including when an irrelevant rabbit IgG was used
Fig. 1 Different ADAM10 species are present in human CSF. a Schematic representation of ADAM10 and its domain organization, which consists
of a pro-domain (Pro), a zinc-binding metalloprotease (Protease) domain, a disintegrin domain (Dis), which binds to integrin cell adhesion molecules, a
cysteine-rich domain (Cys), a variable stalk region, a transmembrane (TM) domain, and a cytosolic domain (Cyto). Not drawn in scale; adapted from
[29]. The potential species resulting from proteolytic removal of the prodomain that are further released from the membrane are indicated (immature
form, proADAM10; mature full-length form, ADAM10f; truncated soluble form, sADAM10). The approximate localizations matching identified ADAM10
peptides in human CSF by nano-LC-MS analysis are indicated (see Additional file 1: TableS1 for additional details). b Western blot of human CSF samples
from controls (non-AD) subjects, resolved with the indicated anti-ADAM10 antibodies. Arrow head indicates a non-specific band (see C). c Control CSF
samples were immunoprecipitated with the ADAM10 N-terminal antibody, and precipitated proteins (IP) were immunoblotted with either ADAM10
(ectodomain) or albumin antibodies. The same CSF samples were incubated, in parallel, with a non-specific rabbit IgG and analyzed as negative controls
(IP control, IPc). For the blot resolved for albumin, the unbound fraction (Unb) is also shown to demonstrated that ADAM10 antibodies is not able to
pull-down albumin
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(Fig. 1c). The ~ 70 kDa band was not present in ADAM10
immunoprecipitates of CSF. When blots were stained with
an anti-albumin antibody a 70 kDa band was observed in
the unbound fraction (Fig. 1c). We did not observe immu-
noreactivity when blots were resolved with a control lack-
ing primary antibody (blots not shown).
Accordingly, based on the pattern of immunoreactivity
with the different antibodies, and the apparent molecular
mass of ADAM10 species reported previously [10, 22,
29, 30], we attributed the 80 kDa band to the immature
form of ADAM10 (proADAM10), and the 55 kDa form
to the mature form (full-length, ADAM10f) derived
from the proADAM10 form by removal of the prodo-
main (194 aa, [31, 32]), and the 50 kDa form to a trun-
cated ADAM10 (soluble, sADAM10), released from the
membrane by metalloproteases (ADAM9/15; [29]).
Interestingly, immunoblotting of CHO cell-conditioned
medium with an anti-C-terminal ADAM10 antibody re-
vealed the presence of bands attributed to soluble
ADAM10f and proADAM10 species (Additional file 2:
FigureS1a). The ~ 70 kDa band was also observed in
cell-conditioned medium, but the immunoreactivity of the
band declined as the amount of FBS in the culture
medium was lowered (Additional file 2: FigureS1b), con-
firming that this band may represent nonspecific staining
associated to albumin.
ADAM10 species in CSF form complexes
Since ADAM10 exists at the plasma membrane as di-
mers [33], we characterized the occurrence of
CSF-ADAM10 oligomers by gradient ultracentrifugation,
which has previously served to illustrate the existence of
different protein complexes in CSF [34, 35]. Western
blotting under denaturing conditions using the
ADAM10 ectodomain antibody, common to all species,
showed that the proADAM10 species accumulated be-
fore to the alkaline phosphatase marker (molecular mass
~ 140–160 kDa), while the sADAM10 species were
identified in denser fractions, between the alkaline phos-
phatase and catalase (molecular mass ~ 232 kDa). Inter-
estingly, the ADAM10f species were resolved in the
denser fractions, close to β-galactosidase (molecular
mass ~ 540 kDa) (Fig. 2). The particular sedimentation
pattern for each ADAM10 species indicated that, at
least, sADAM10 and ADAM10f could form large com-
plexes in CSF.
Mature forms of ADAM10 are decreased in AD CSF
After assigning the different ADAM10 immunoreactive
species present in CSF as full-length (~ 55 kDa,
ADAM10f ) or truncated (~ 50 kDa, sADAM10) mature
species, as well as immature forms (~ 80 kDa, proA-
DAM10), we assessed whether the concentrations of
these species are altered in AD. We analyzed CSF sam-
ples from 27 AD patients and 26 NADC. The core AD
biomarkers were measured using ELISA, confirming ele-
vated CSF T-tau and P-tau and low levels of Aβ42 in the
AD samples (Table 1). Regarding ADAM10 immunore-
activities, we found that the 55 kDa species decreased in
abundance (~ 40%; p = 0.005) in AD compared to NADC
subjects (Fig. 3). A similar decrease was found for the
truncated 50 kDa fragment (~ 36%; p = 0.004), whereas,
the concentration of the 80 kDa immature ADAM10
form was unchanged (p = 0.44). Despite the different
evolution of the mature and immature ADAM10 spe-
cies, we observed a trend towards a decrease in the
non-specific 70 kDa band, attributed to albumin. The
CSF/serum albumin ratio is accepted as a more sensitive
and adequate parameter for the demonstration of a
blood-brain damage than CSF-protein or CSF-albumin
[36]. We recently studied the CSF/serum albumin ratio
in a large cohort of patients diagnosed with AD and
found no evidence of blood-brain barrier dysfunction in
AD. We assume that a higher CSF/serum albumin may
represent concomitant cerebrovascular pathology [37].
In the patient cohort included in this study, we found a
Fig. 2 Characterization of CSF-ADAM10 complexes by sucrose gradient ultracentrifugation. CSF samples (NADC) were fractionated on 5–20%
sucrose density gradients. The fractions (collected from the top of each tube) were immunoblotted using the ectodomain antibody specific for a
domain common to all the soluble CSF-ADAM10 species. Enzymes of known sedimentation coefficient, alkaline phosphatase (P, 6.1S; ~ 140–160 kDa),
catalase (C, 11.4S; ~ 232 kDa), and β-galactosidase (G, 16.0S; ~ 540 kDa) were used as internal markers. A representative case from three independent
experiments is shown
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non-significant (p = 0.063) trend towards a decrease in the
CSF/serum albumin ratio for the AD subjects (5.8 ± 0.6)
compared to NADC (7.4 ± 0.6). For this reason, to prevent
a potential misinterpretation of the decrease in ADAM10
species, we examined the (50 + 55 kDa)/80 kDa ratio for
each sample based on the direct analysis of the western
blots. Accordingly to our previous analysis, the ratio of
mature/immature ADAM10 species also displayed differ-
ences between AD and NADC groups, indicating that a
decrease in mature ADAM10 species in AD is not associ-
ated with a lower protein content of the AD samples or a
loading artifact (Fig. 3c).
We further tested whether CSF-ADAM10 complexes are
altered in AD cases. CSF-ADAM10 complexes were frac-
tioned, from three AD and three NADC representative
cases, using sucrose-density gradient fractionation, and
then resolved by western blotting under denaturing condi-
tions (Additional file 3: FigureS2). Peaks of the
CSF-ADAM10 complexes were identified in similar frac-
tions for all the AD and ND cases tested, indicating that all
complexes are present in AD CSF, and the nature of the
complexes is not affected by the pathological conditions.
Interestingly, levels of sADAM10 and ADAM10f were
correlated, albeit weakly, in CSF from NADC subjects
(R = 0.39; p = 0.048), but not in AD patients (R = 0.25;
p = 0.20). In NADC subjects, no correlation was observed
between proADAM10 and ADAM10f (R = 0.30; p = 0.13)
or proADAM10 and sADAM10 (R = 0.15 p = 0.46). In the
AD subjects, these correlations were not evident for both
proADAM10 and ADAM10f (R = 0.05; p = 0.81) or for
proADAM10 and sADAM10 (R = 0.12; p = 0.56). No cor-
relations were observed with age. Although the groups
were not balanced regarding gender (see Table 1), we did
not observe differences in any parameter between males
and females in the AD group. Levels of the ADAM10 spe-
cies did not correlate with the core AD biomarkers in
NADC, while in AD samples, higher Aβ42 levels corre-
lated with lower ADAM10f levels (R = 0.43; p = 0.027), but
not correlations were observed with the levels of
sADAM10 species (Additional file 4: FigureS3).
Discussion
There is a need to identify additional CSF biomarkers of
AD. The knowledge that APP metabolism and Aβ produc-
tion and aggregation are key steps in AD pathogenesis
makes proteins involved in the pathological processing of
APP, including secretases such as ADAM10, reasonable
candidates for analysis in CSF. However, since secretases
are transmembrane proteins, their assessment in CSF was
not considered until recent years.
Previous studies have revealed that, in addition to pro-
teins, CSF contains many endogenous peptides [38, 39],
including ADAM10 peptides [26]. In this study, we dem-
onstrate the presence in human CSF of the mature and
immature full-length ADAM10 protein, as well as a mem-
brane cleaved large fragment (sADAM10). As sADAM10
can be released by proteolytic processing from the mem-
brane [29], this suggests the potential for truncated iso-
forms to be present in CSF. Indeed, recent reports
indicate the possibility that ADAM10 levels can even be
Fig. 3 Decreased levels of mature ADAM10 species in AD CSF samples. a Representative blot of ADAM10 species immunoreactive to an ectodomain
antibody in the CSF samples from 27 AD patients and 26 age-matched non-AD controls (NADC). Arrow head indicates a non-specific band. b
Densitometric quantification of ADAM10 immunoreactivity from the 55 kDa species attributed to the mature form (ADAM10f), the truncated 50 kDa
(sADAM10), and the 80 kDa immature form (proADAM10). Equal volumes of CSF were loaded in each lane and Ponceau staining served to monitor
potential loading inaccuracies (none of the major bands detected by Ponceau staining displayed significant differences between groups). c The ratio
derived from the immunoreactivity for the mature 50 and 55 kDa bands relative to that for the immature 80 kDa band estimated in each sample
[(50 kDa + 55 kDa)/80 kDa] is also shown. Data are presented as means ± SEM: *p≤ 0.005
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measured in human serum by an enzyme-linked immuno-
sorbent assay (ELISA; [40, 41].
In our previous study [26] using LC-MS analysis, we
identified several short peptide fragments of ADAM10
in human CSF, matching sequences located at the
N-terminus of the protein as well peptide fragments lo-
cated close to the transmembrane domain of the protein.
In this study, several different molecular mass bands of
ADAM10 were detected by western blot analysis using
N- and C-terminal anti-ADAM10 antibodies. Thus, in
addition to a sADAM10 isoform attributed to the immu-
noreactive band of ~ 50 kDa molecular mass, other
ADAM10 species retaining the intracellular C-terminal
domain are present in the CSF. Moreover, as some of
the sequences identified by LC-MS analysis were hom-
ologous to the N-terminal prodomain, this indicated
that, unexpectedly, immature proADAM10 also reached
the CSF. Thus, other full-length isoforms of the protein
co-exist in the CSF with sADAM10. The presence of
proADAM10, together with ADAM10f, has been de-
scribed at the cell surface [10].
The mechanisms by which these membrane-resident
ADAM10 species reach the CSF are unknown, but neur-
onal death may be a contributing factor. Interestingly,
proADAM10 and ADAM10f were also detected in cul-
ture media from CHO cells. Abundant ADAM10 has
been found in exosomes of bovine endometrial stromal
cells cultured at hypoxic conditions [42]. Thus, an exo-
somal contribution of ADAM10-CSF cannot be dis-
counted. Interestingly, ADAM10 is also enriched in
synaptic vesicles [43], being one of many synaptic pro-
teins identified and measured in CSF [44]. In this con-
text, we and others have reported evidence of the
presence in the CSF of “unprocessed” forms of several
transmembrane proteins, such as BACE1 [34], APP [35,
45], and the multi-pass presenilin-1 (PS1) [18, 34]. Thus,
the existence of a membrane-resident protein in CSF is
not an unusual finding [46]. Recently, we also character-
ized in CSF the existence of C-terminal fragments of
APP, which include the transmembrane domain [47].
The occurrence in CSF of proteins which still maintain
their transmembrane and intracellular domains is also
relevant for the development of strategies for their quanti-
tative estimation. ADAM10, similar to many other trans-
membrane proteins exists as a dimer in the brain [33].
Both the transmembrane [48] and cytoplasmic [33] do-
mains can participate in dimerization of ADAM10, a fea-
ture that may be is an inherent property of ADAM
metalloproteinases. In the present study, we demonstrated
by gradient centrifugation that sADAM10 and ADAM10f
are present in the CSF as large complexes. Further studies
will be necessary to clarify the biochemical properties of
these homomeric complexes, but our preliminary analysis
indicates that the species in NADC CSF are similar, if not
identical to the species in the AD CSF. We have previ-
ously demonstrated the occurrence of APP heteromers in
CSF, comprising both sAPPα/sAPPβ and also soluble
full-length APP, and we have shown that these heteromers
affect the determination of sAPP by ELISA [35]. Given
that the distinct ADAM10 species also form complexes,
the development of an accurate ELISA protocol for the es-
timation of CSF-ADAM10 levels may require more know-
ledge about the potential variable stoichiometry and
stability of these complexes. In fact, our early attempts to
assess ADAM10-CSF levels by ELISA have resulted in
poorly reproducible data (~ 60% intra-assay variability in
CSF samples; ELISA kit from MyBioSource, Inc. San
Diego, CA, USA). A previous study also reported difficul-
ties in assessing ADAM10 in CSF, discarding their pres-
ence in the fluid [49]. In this study, to circumvent this
issue, we analyzed ADAM10-CSF levels by SDS-PAGE.
Our determination of the different species of
ADAM10 in CSF by western blotting indicated that, in
AD cases, there is a decrease in sADAM10 and
ADAM10f, but not in the immature forms. Since amy-
loidogenic processing of APP is expected to be altered in
the Alzheimer brain, parallel changes in the levels of
α-secretase and β-secretase might be expected. However,
it is still unclear if α-secretase and β-secretase are in-
versely correlated during pathological progression, as the
proteolytic products sAPPα and sAPPβ displayed similar
trends in the CSF [45]. Data on ADAM10 in human
brain are scarce, but the majority of the data indicate an
overall decrease in ADAM10 mRNA, protein, and/or ac-
tivity in the brain of AD patients compared to
age-matched controls [50]. However, at least in platelets,
the decrease of ADAM10 protein in AD patients is not
caused by a reduction in ADAM10 mRNA [51]. Thus,
the regulation of expression and activity of ADAM10
may be complex, being regulated by several pathways,
epigenetically, and at translational and post-translational
levels [50], and affected by normal aging [30]. In this
context, it may be important to evaluate α-secretase ac-
tivity in CSF. Enzymatic activity assays in CSF are usu-
ally based on the use of specific substrates (synthetic
peptides) favorable for the assessment of a concrete ac-
tivity, but as mentioned previously, other enzymes, in
addition to ADAM10, display α-secretase-like activity.
Indeed, elevated activity levels for ADAM17/TACE have
been found in both CSF [19] and plasma [20, 21] from
subjects with AD. It appears important to decipher the
physiopathological significance of the differential regula-
tion in AD for ADAM10 and ADAM17. Anyhow, in the
view of the apparent increase in ADAM17 levels and de-
crease in ADAM10 protein levels in AD CSF, it is ques-
tionable whether an enzymatic activity assay for
ADAM10 in CSF, based in the use of synthetic peptides
(which can be cleaved by multiple proteases), should be
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used to measure changes in the CSF α-secretase activity
of AD patients. The general requirements for secretase
cleavage are not strict, and we cannot exclude the possi-
bility that other CSF enzymes that may cleave the syn-
thetic peptides also being detected. Moreover, emerging
evidence indicates that the plasma membrane with its
unique dynamic properties may additionally play an im-
portant role in controlling sheddase function, as physi-
cochemical properties of the lipid bilayer that govern the
action of ADAM-proteases [52]. Accordingly, determin-
ation of enzymatic activities does not appear to be the
most adequate and sensitive molecular tool to evaluate
ADAM10, and other secretases, as a potential CSF bio-
markers. Therefore, only ELISA assays based on
pan-specific antibodies for concrete ADAM10 species,
and including pre-treatment methods designed to disag-
gregate complexes, may be a reliable approach to assess
ADAM10 protein levels and enzymatic activity.
Despite the limited precision of western blotting for
quantitative analysis, we consider that mature forms of
ADAM10 in CSF constitute potential new biomarkers of
AD. The western blotting technique is also an important
limitation regarding the number of cases to analyze. A
corroborative study in a large and independent cohort
should be necessary to assess the potential of this new
biomarker for AD diagnosis. New studies should also ad-
dress analysis of aging in normal conditions, adequate
balance of gender in the pathological group, and more
importantly, the specificity of the changes for AD con-
fronting other dementias. In this study, we defined neu-
rochemically AD and NADC subjects based on the
levels of classical AD biomarkers. The NADC subjects
included in this study also exhibited cognitive impair-
ment; therefore, the control group is not totally com-
prised of healthy individuals and probably includes
several non-AD conditions. Despite the inherent diffi-
culty of the clinical diagnosis to truly assess the potential
of new diagnostic biomarkers, tentative studies including
other dementias clinically diagnosed will be of particular
relevance, especially with longitudinal follow-up and es-
tablishment of definitive diagnosis. The involvement of
ADAM10 in other pathological processes such as trau-
matic brain injury, inflammation, brain tumors, stroke,
and psychiatric diseases [48, 53] also deserves the ana-
lysis of CSF-ADAM10 levels.
Conclusions
Our present findings provide sufficient evidence to
justify further studies focusing on the possibility of
monitoring specific soluble forms of ADAM10 and to
evaluate the progress and feasibility of developing
molecular tools for this potential new CSF biomarker
for AD.
Additional files
Additional file 1: Table S1. Identified ADAM10 peptides in CSF.
(DOCX 17 kb)
Additional file 2: Figure S1. Soluble mature and immature ADAM10
species are present in cell medium by CHO cells. a Western blot of cell
extract (cell) and culture medium (cell media) from CHO cell cultures
grown in presence of 5% FBS, resolved with the anti-ADAM10 C-terminal
antibody. b Cell medium from CHO cells grown in presence of 0.5 or 1%
FBS are also shown. Arrow head indicates a non-specific band attributed
to albumin (see Fig. 1). (TIF 6444 kb)
Additional file 3: Figure S2. Unaltered ADAM10 complexes in AD CSF.
(A) Representative blot of ADAM10 complexes in CSF from AD subjects
and age-matched non-AD controls (NADC). Three representative AD
and NADC cases were analyzed, in which the distribution of ADAM10
complexes displayed similar sedimentation patterns. Blots were resolved
with an ADAM10 ectodomain antibody (domain common to all the CSF-
ADAM10 species). (TIF 1707 kb)
Additional file 4: Figure S3. Correlation of mature ADAM10 species
with Aβ42 levels in CSF samples. A linear regression analysis was used to
assess the correlation between the Aβ42 levels obtained by ELISA
(see Table 1) and ADAM10f, or sADAM10 in the samples from age-matched
NADC (closed symbol, solid lines) and AD patients (open symbol, dotted
lines). Correlations for T-tau or P-tau were non-significant (not shown).
The linear regression coefficient (R) and p values for each correlation are
shown (n.s.: non-significant p value). (TIF 476 kb)
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